标题
JAK Inhibitors for Atopic Dermatitis: An Update
作者
关键词
-
出版物
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-12-07
DOI
10.1007/s40257-018-0413-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immunologic, microbial, and epithelial interactions in atopic dermatitis
- (2018) Patrick M. Brunner et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study
- (2018) Elena Peeva et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
- (2018) H. Nakagawa et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
- (2018) G.J. Schmieder et al. BRITISH JOURNAL OF DERMATOLOGY
- Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
- (2018) Sumit Kunwar et al. CLINICAL RHEUMATOLOGY
- Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
- (2018) Ian C. Scott et al. DRUG SAFETY
- Early-onset pediatric atopic dermatitis is characterized by T H 2/T H 17/T H 22-centered inflammation and lipid alterations
- (2018) Patrick M. Brunner et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Serum from Asian patients with atopic dermatitis is characterized by T H 2/T H 22 activation, which is highly correlated with nonlesional skin measures
- (2018) Huei-Chi Wen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
- (2018) Andreas Wollenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
- (2018) Hidemi Nakagawa et al. JOURNAL OF DERMATOLOGY
- 1083 Effect of RVT-502 therapy in the NC/Nga mouse model of atopic dermatitis
- (2018) K. McHale et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
- (2018) Michael L. Vazquez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- (2018) Deep Joshipura et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
- (2018) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Topical Janus kinase inhibitors: A review of applications in dermatology
- (2018) Anna-Marie Hosking et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
- (2018) Satoshi Kubo et al. Frontiers in Immunology
- Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation
- (2018) Riana D. Sanyal et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- LB1575 SNA-125, a novel selective kinase inhibitor, improves clinical symptoms in a mouse model of psoriasis
- (2018) L. Bertarione et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents
- (2017) Atsuo Tanimoto et al. EXPERIMENTAL DERMATOLOGY
- Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest
- (2017) William J. Sandborn et al. GASTROENTEROLOGY
- Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march
- (2017) Tali Czarnowicki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
- (2017) Patrick M. Brunner et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Janus kinase inhibitors display broad anti-itch properties: A possible link through the TRPV1 receptor
- (2017) Tomoki Fukuyama et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
- (2017) Maya Deeb et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- 313 A pathogenic role for Th22/IL-22 in atopic dermatitis is established by a placebo-controlled trial with an anti IL-22/ILV-094 mAb
- (2017) E. Guttman-Yassky et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita
- (2017) Tamás Németh et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- (2017) Cheryl B. Bayart et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study
- (2017) Yoshiya Tanaka et al. Modern Rheumatology
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
- (2017) José Ramón Maneiro et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis
- (2017) Yong Chen et al. Scientific Reports
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential
- (2017) Bindee Kuriya et al. Therapeutic Advances in Musculoskeletal Disease
- The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
- (2017) Patrick M. Brunner et al. Scientific Reports
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
- (2016) Mohamed-Eslam F. Mohamed et al. CLINICAL PHARMACOKINETICS
- Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis
- (2016) Britta C. Martel et al. EXPERIMENTAL DERMATOLOGY
- Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
- (2016) Saakshi Khattri et al. EXPERIMENTAL DERMATOLOGY
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Early-onset pediatric atopic dermatitis is T H 2 but also T H 17 polarized in skin
- (2016) Hitokazu Esaki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Advances in atopic dermatitis in 2015
- (2016) Takashi Nomura et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
- (2016) Thomas Werfel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Downregulation of the Syk Signaling Pathway in Intestinal Dendritic Cells Is Sufficient To Induce Dendritic Cells That Inhibit Colitis
- (2016) Long Hang et al. JOURNAL OF IMMUNOLOGY
- Spleen Tyrosine Kinase Mediates EGFR Signaling to Regulate Keratinocyte Terminal Differentiation
- (2016) Nan-Lin Wu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
- (2016) Y. Tanaka et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- (2016) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults
- (2016) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
- (2016) Diamant Thaçi et al. LANCET
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- (2016) Brittany G. Craiglow et al. JAMA Dermatology
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis
- (2015) D Roblin et al. ACTA DERMATO-VENEREOLOGICA
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
- (2015) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Ruxolitinib: A Review in Polycythaemia Vera
- (2015) Kate McKeage DRUGS
- Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
- (2015) Greg L. Plosker DRUGS
- The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization
- (2015) Shinji Noda et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling
- (2015) Wataru Amano et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection
- (2015) Hitokazu Esaki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Syk Tyrosine Kinase Is Critical for B Cell Antibody Responses and Memory B Cell Survival
- (2015) Jochen A. Ackermann et al. JOURNAL OF IMMUNOLOGY
- Syk Mediates IL−17-Induced CCL20 Expression by Targeting Act1-Dependent K63-Linked Ubiquitination of TRAF6
- (2015) Nan-Lin Wu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
- (2015) Lauren L. Levy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- (2015) Ali Jabbari et al. EBioMedicine
- Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
- (2014) Donald Y.M. Leung et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
- (2014) Jennifer D. Hamilton et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
- (2014) Lisa A. Beck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo
- (2014) Helen L. Wright et al. RHEUMATOLOGY
- Definition and management of ruxolitinib treatment failure in myelofibrosis
- (2014) A Pardanani et al. Blood Cancer Journal
- Syk Signaling in Dendritic Cells Orchestrates Innate Resistance to Systemic Fungal Infection
- (2014) Paul G. Whitney et al. PLoS Pathogens
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders
- (2013) Yasuko Furumoto et al. BIODRUGS
- A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
- (2013) W.C. Ports et al. BRITISH JOURNAL OF DERMATOLOGY
- Jakpot! New small molecules in autoimmune and inflammatory diseases
- (2013) Kamran Ghoreschi et al. EXPERIMENTAL DERMATOLOGY
- Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis
- (2013) Mayte Suárez-Fariñas et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor
- (2013) Y. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New Insights into Atopic Dermatitis: Role of Skin Barrier and Immune Dysregulation
- (2013) Donald Y.M. Leung ALLERGOLOGY INTERNATIONAL
- A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
- (2012) Aman Samrao et al. ARCHIVES OF DERMATOLOGY
- The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development
- (2012) H. S. Li et al. BLOOD
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
- (2012) Apostolos Kontzias et al. CURRENT OPINION IN PHARMACOLOGY
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency
- (2012) Sanja Kezic et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
- (2012) Julia K. Gittler et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spleen Tyrosine Kinase Inhibitors (SYK) as Potential Treatment for Autoimmune and Inflammatory Disorders
- (2012) Ahmed F. Abdel-Magid ACS Medicinal Chemistry Letters
- Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis
- (2011) Alen Ostojic et al. Future Oncology
- The Transcription Factor STAT3 Is Required for T Helper 2 Cell Development
- (2011) Gretta L. Stritesky et al. IMMUNITY
- Transcriptional regulation by STAT6
- (2011) Shreevrat Goenka et al. IMMUNOLOGIC RESEARCH
- Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
- (2011) Mark Boguniewicz et al. IMMUNOLOGICAL REVIEWS
- Involvement of Tyrosine Kinase-2 in Both the IL-12/Th1 and IL-23/Th17 Axes In Vivo
- (2011) M. Ishizaki et al. JOURNAL OF IMMUNOLOGY
- STAT6-Dependent Regulation of Th9 Development
- (2011) R. Goswami et al. JOURNAL OF IMMUNOLOGY
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- STAT5 Is Critical To Maintain Effector CD8+ T Cell Responses
- (2010) P. Tripathi et al. JOURNAL OF IMMUNOLOGY
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Signal transduction and Th17 cell differentiation
- (2009) John J. O'Shea et al. MICROBES AND INFECTION
- Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development
- (2009) Stephen Malin et al. NATURE IMMUNOLOGY
- Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
- (2008) Byung Eui Kim et al. CLINICAL IMMUNOLOGY
- Atopic Dermatitis
- (2008) Thomas Bieber NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now